These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 24431392)

  • 21. Clinical remission in patients with active psoriatic arthritis treated with adalimumab and correlations in joint and skin manifestations.
    Van den Bosch F; Kavanaugh A; Kron M; Kupper H; Mease PJ
    J Rheumatol; 2015 Jun; 42(6):952-9. PubMed ID: 25834212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis.
    Lupoli R; Pizzicato P; Scalera A; Ambrosino P; Amato M; Peluso R; Di Minno MN
    Arthritis Res Ther; 2016 Dec; 18(1):297. PubMed ID: 27964760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value.
    Coates LC; Gottlieb AB; Merola JF; Boone C; Szumski A; Chhabra A
    J Rheumatol; 2019 Feb; 46(2):160-165. PubMed ID: 30323006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors.
    Chimenti MS; Triggianese P; Conigliaro P; Tonelli M; Gigliucci G; Novelli L; Teoli M; Perricone R
    Clin Rheumatol; 2017 Oct; 36(10):2253-2260. PubMed ID: 28762060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data.
    Coates LC; Helliwell PS
    Arthritis Care Res (Hoboken); 2010 Jul; 62(7):965-9. PubMed ID: 20589696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of cardiovascular risk factors on the achievement of therapeutic goals in psoriatic arthritis: is there any association?
    Queiro R; Cañete JD
    Clin Rheumatol; 2018 Mar; 37(3):661-666. PubMed ID: 29380165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis.
    Wervers K; Vis M; Tchetveriko I; Gerards AH; Kok MR; Appels CWY; van der Graaff WL; van Groenendael JHLM; Korswagen LA; Veris-van Dieren JJ; Hazes JMW; Luime JJ
    Arthritis Care Res (Hoboken); 2018 Dec; 70(12):1764-1770. PubMed ID: 29609220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries.
    Orbai AM; Perin J; Gorlier C; Coates LC; Kiltz U; Leung YY; Palominos PE; Cañete JD; Scrivo R; Balanescu A; Dernis E; Tälli S; Ruyssen-Witrand A; Soubrier M; Aydin S; Eder L; Gaydukova I; Lubrano E; Kalyoncu U; Richette P; Husni ME; Smolen JS; de Wit M; Gossec L
    Arthritis Care Res (Hoboken); 2020 Dec; 72(12):1772-1779. PubMed ID: 31609525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Achieving Minimal Disease Activity on the Progression of Subclinical Atherosclerosis and Arterial Stiffness: A Prospective Cohort Study in Psoriatic Arthritis.
    Cheng IT; Shang Q; Li EK; Wong PC; Kun EW; Law MY; Yip RM; Yim IC; Lai BT; Ying SK; Kwok KY; Li M; Li TK; Zhu TY; Lee JJ; Chang MM; Szeto CC; Yan BP; Lee AP; Tam LS
    Arthritis Rheumatol; 2019 Feb; 71(2):271-280. PubMed ID: 30144299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?
    Kilic G; Kilic E; Nas K; Kamanlı A; Tekeoglu İ
    Rheumatol Int; 2019 Jan; 39(1):73-81. PubMed ID: 30426235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and Patient-reported Outcomes in Patients with Psoriatic Arthritis (PsA) by Body Surface Area Affected by Psoriasis: Results from the Corrona PsA/Spondyloarthritis Registry.
    Mease PJ; Karki C; Palmer JB; Etzel CJ; Kavanaugh A; Ritchlin CT; Malley W; Herrera V; Tran M; Greenberg JD
    J Rheumatol; 2017 Aug; 44(8):1151-1158. PubMed ID: 28620063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.
    Lubrano E; De Socio A; Perrotta FM
    J Rheumatol; 2017 Aug; 44(8):1159-1164. PubMed ID: 28572467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study.
    Napolitano M; Costa L; Caso F; Megna M; Scarpa R; Balato N; Ayala F; Balato A
    Clin Rheumatol; 2017 Jul; 36(7):1589-1593. PubMed ID: 28567556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study.
    Chimenti MS; Ortolan A; Lorenzin M; Triggianese P; Talamonti M; Costa L; Caso F; Favero M; Teoli M; Galluzzo M; Scarpa R; Punzi L; Perricone R; Ramonda R
    Clin Rheumatol; 2018 Feb; 37(2):397-405. PubMed ID: 29302829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature.
    Gossec L; McGonagle D; Korotaeva T; Lubrano E; de Miguel E; Østergaard M; Behrens F
    J Rheumatol; 2018 Jan; 45(1):6-13. PubMed ID: 29142032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treating Psoriatic Arthritis to Target: Defining the Psoriatic Arthritis Disease Activity Score That Reflects a State of Minimal Disease Activity.
    Perruccio AV; Got M; Li S; Ye Y; Gladman DD; Chandran V
    J Rheumatol; 2020 Mar; 47(3):362-368. PubMed ID: 31203221
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Remission in psoriatic arthritis: Definition and predictors.
    Alharbi S; Ye JY; Lee KA; Chandran V; Cook RJ; Gladman DD
    Semin Arthritis Rheum; 2020 Dec; 50(6):1494-1499. PubMed ID: 32145969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study.
    Costa L; Caso F; Ramonda R; Del Puente A; Cantarini L; Darda MA; Caso P; Lorenzin M; Fiocco U; Punzi L; Scarpa R
    Immunol Res; 2015 Feb; 61(1-2):147-53. PubMed ID: 25395342
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis.
    Iannone F; Nivuori M; Fornaro M; Venerito V; Cacciapaglia F; Lopalco G
    Rheumatology (Oxford); 2020 Jul; 59(7):1599-1606. PubMed ID: 31652315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.